Pharmaceuticals company Orchid Pharma announced FY24 results: Sales for FY24 were at Rs 819.4 crore, up by 23% YoY. PAT surged 71.60% YoY to Rs 94.7 crore in FY24. A highlight of this quarter has been the progress of Orchid Pharma’s novel drug Enmetazobactam. Speaking on the Q4 results, Manish Dhanuka, Managing Director, Orchid Pharma said, “Our revenues have experienced a significant increase over the past year. We have concentrated on maximizing capacity utilization while maintaining stringent cost controls. The positive outcomes of these initiatives, combined with a robust product pipeline and Capex of more than Rs 800 Crore over the next few years, indicate promising future prospects.” Result PDF